Immunotech Biopharm Ltd. announce that the Company has completed the first patient enrolment for its Phase II clinical trial for CAR-T-19 injection ("CAR-T-19 Injection") in the PRC, which marked a key milestone of the Group's development in its product pipeline. CAR-T-19 Injection is indicated for the treatment of pediatric and young adult patients up to and including the age of 25 with relapsed/refractory B cell acute lymphoblastic leukaemia ("B-ALL"). Based on the progress of clinical trial for CAR-T-19 Injection, it is expected that the target patient enrolment would complete by the end of 2025 and the preliminary analysis and results would be published in the first half of 2026.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.04 HKD | -8.43% |
|
-5.59% | -39.20% |
Jun. 21 | Immunotech Biopharm Unit Sells 80 Million Yuan of Certificates of Deposit | MT |
Mar. 29 | Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023 | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-39.20% | 219M | |
+20.63% | 127B | |
+24.16% | 27.67B | |
-20.17% | 20.33B | |
-16.06% | 16.79B | |
-18.07% | 15.63B | |
-47.70% | 14.65B | |
+11.92% | 14.84B | |
+58.32% | 14.43B | |
+149.98% | 12.49B |
- Stock Market
- Equities
- 6978 Stock
- News Immunotech Biopharm Ltd
- Immunotech Biopharm Ltd Announces First Patient Enrolled in the Phase II Clinical Trialfor Car-T-19 Injection